CRP and prostate cancer: For instance, a meta-analysis showed that higher concentrations of circulating C-reactive protein (CRP), a non-specific marker of systemic inflammation, were associated with a higher risk of breast cancer (hazard ratio (HR)=1.14, 95% confidence interval (CI) 1.01-1.28), lung cancer (HR=2.03, 95% CI 1.59-2.60), colorectal cancer (OR=1.34, 95% CI 1.11-1.60) and prostate cancer (HR=1.09, 95% CI 1.03-1.15) (17).